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THE BEGINNINGS
My special interests have always been the heart and kidney – you
may say I was put through my paces to become both, a physician
(anatomic and surgical pathologist) and a translational researcher.
This had three reasons: (i) I always wanted to understand how
something evolved rather than just to learn it by heart ; (ii) I am
impressed by tradition, but also eager to learn something new,
and (iii) it always appealed to me that my father – as a doctor of
internal medicine – could help other people.
The first of these reasons:
(i) Was based on my history class in high school in Wies-
baden, Hessen, Germany. In my mind, I wanted to become
an archeologist to explore so many unknown achievements
of the antiquities, which have influenced the development
of mankind to this day. Fortunately, my parents allowed me
to see many ancient places and also modern living condi-
tions in the Eastern Mediterranean and as well as in Mid-
dle and South America. This knowledge helped me more
than once to bridge cultural and social gaps, and to fos-
ter an understanding of different people with whom I later
worked.
(ii) My respect for tradition was born while in the boy scouts in
a group called “Wilhelmus” and in the Oranienschule (high
school – gymnasium) in Wiesbaden, the former capital of old
Hessen-Nassau. I admired the fight for freedom by Wilhelm
von Nassau – Oranien, the later King of the Netherlands.
Nassau-Oranien and its shield with the three golden lilies on
a blue ground held a promise to succeed against the odds.
(iii) And medicine? Well, it was my second choice after archeology,
and when I finished my “Abitur” (the high school diploma
in Germany), things looked rather bleak for classic arche-
ology. Therefore, I did my premedical training and decided
medicine was worth a try.
THE MAINZ YEARS
The next event that determined my later fate was the opportu-
nity to visit different preclinical departments at the Johannes-
Gutenberg-University of Mainz, where I had started my medical
school studies at the age of 18 years. In anatomy, a DNA molecule
was made visible by rotary shadowing that was on display in the
electron microscope. This was for me the most impressive single
event in these 2 years of preclinical medicine. Besides, I liked the
insights that I could gain in the biochemistry class, which was
taught to us so that we should begin to understand how chemical
formulas translated into the meaningful processes regulating life
and death.
After passing the so-called “Physikum” the most impressive
clinical–theoretical subject was the renal course taught by the new
head of the department, Wolfgang Thoenes, M.D., Professor of
Pathology. It was all black board and colored chalk, kodachromes
were the exception! It was a time with no sonography, CT, or
MRI – so autopsy pathology was essential to know from what the
patient ultimately was suffering and had died. The daily inter-
actions between the pathologist and the clinical colleagues as
they discussed the findings were most enlightening. Over the past
30 years, the average age of the patient has increased by 10 years and
now involves treatment of diseases that were unthinkable when I
started in 1980. This development increased the complexities of
diagnoses and therapies alike, which, in my mind, can hardly any-
where be better evaluated than in a clinical–pathological autopsy
conference. The problems of the existing diagnostic tools, the often
non-symptomatic and, thus, undiagnosed disease manifestations,
and iatrogenic complications have been and are still fascinating
to me. Thus, I decided to start with a 1- to 2-year training in
Pathology.
I asked for a medical thesis in the Pathology department. I expe-
rienced the thrill of being offered to work with a subject, which I
had found enticing before: this time it was the electron microscope.
www.frontiersin.org March 2015 | Volume 2 | Article 9 | 1
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fries The wish to cure and the curiosity to investigate
1975 was a time where electron microscopy was the ultimate tool
in Pathology. My thesis work took me 4 years to complete up to
the end of my medical studies. The microscopic chamber allowed
12 individual pictures to be taken; and I took about 2000 pic-
tures . . . My mentor was Karl-Heinz Langer, M.D., Professor of
Pathology, who was a diligent and skillful experimental pathologist
and electron microscopist (1).
INTO CLINICAL PRACTICE AND THE NAVY
After an interesting clinical year in the Hospital of Idar-Oberstein,
I did my national military service as medical doctor in the rank
of a lieutenant commander on board of the German frigate F223,
“Karlsruhe” (Figure 1). It was basic medicine at its finest: from
pulling teeth, extracting nails, and other kinds of small surgery,
including the removal of several small scrotal lipomas with an
icing spray as anesthesia (“my wife said, you can do it doctor!”).
I learned how to stand up to fight for my patients’ rights when
being questioned by a commanding officer. During a three-month
trip across the Atlantic, I refused to do a finger amputation (not
alone for medical reasons) on a commissioned officer of an English
frigate, preserving his gripping function through an operation
in the hospital of Halifax in Canada. A diving course in Kiel
and a futile search for a rating who went overboard in the wild
seas of the Skagerrak in January were further memorable events.
After my service, I choose a position as resident in the Pathology
FIGURE 1 | Sometimes my life depended on a rope . . .. Highline
maneuver, German Navy, North Sea, 1979.
department in Mainz,where I had done my doctoral thesis, starting
on May 1, 1980.
AS RESIDENT IN MAINZ, GERMANY
There was a different understanding at that time of what it meant
to strive for a habilitation than today, which Wolfgang Thoenes – a
world renowned specialist on glomerulonephritis (GN) – enforced
like a code of honor with all his coworkers. The work we did
was supposed to help to understand, improve, and set new stan-
dards in the chosen field in pathology: such as the development of
a renal tumor classification (Stephan Störkel, M.D., Professor of
Pathology); the classification of post infectious GN (Karin Sorger,
M.D., Professor of Pathology), the classification of membranopro-
liferative GN (D. Anders, M.D.), micropuncture studies, granu-
loma formation, and glomerular filtration using Ferritin as tracer
(Karl-Heinz Langer, M.D., Professor of Pathology), Alport Syn-
drome, and renal transplant rejection (Hans-Joachim Rumpelt,
M.D., Professor of Pathology). Moreover, to this “code,” I still feel
obliged today. Looking back, it was also a time of some nice social
interactions (Figure 2).
I stayed in Mainz since I liked the identification of shapes and
colors in tissue disease – very similar to the skills that one need for
the identification of pottery or pieces of a fries in archeology. My
interest in photography came in handy.
Already then, I was intrigued by applying new technology to
analyzing “old” problems. The findings in proteinuric disease –
particularly the so-called fusion of podocytic processes, being
in reality a retraction and flattening of the podocytes – was a
pathophysiologically puzzling alteration. Applying a morphome-
tric analysis to a large number of adult and children’s cases in
electron microscopic pictures taken by myself (20 capillary loops
per glomerulus; 5 glomeruli per case, 5 cases per etiologic group;
5 groups each for adult and children) took me 2 years to finish
(mostly in the evenings and at night). I purchased the new hand
held calculator by Hewlett Packard; model HP-41C (about 750
DM in 1980) with its newly released statistic module, in order to
analyze the enormous amounts of data (and which is still func-
tioning today, 30 years later!). To make matters worse, Dr. Thoenes
FIGURE 2 | Advent celebration in good, old tradition in the electron
microscopy lab; Department of Pathology, University of Mainz, 1982.
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Fries The wish to cure and the curiosity to investigate
did not trust the data as much as he trusted his visual evaluation of
pictures: how could I propose that only about 10% of all podocytes
were flattened and retracted irrespective of the underlying protein-
uria and disease entity? – I insisted (“Advent,Advent. Is there a light
of hope?” Dr. Thoenes asked me before Christmas of 1986) finally,
in 1987 and after much ado, the paper was published in Kidney
International (2). Persistence and one’s belief in one’s own data is
a lesson one has to learn.
What irritated me a lot then and still does today, however, was
and is the persisting belief that experimental research can be done
besides medical routine – in the evenings, at weekends, and in your
own holidays (as I was told starting as a resident) being not given
any protected, extra time, very much in contrast to conditions our
American colleagues can enjoy, with fixed times for clinical but
also research activities if desired. The major difference, however, is
the fact that the NIH pays for the research time, provided one has
his or her own (!) grant, while the clinic pays only one’s clinical
activities – in contrast to how it is in Germany.
My first talk was given at the pathology meeting taking place
each year in Mainz. Since it was a chance for the young residents to
get first experiences in an oral presentation, it was charmingly also
called “debutant ball.” I had only one night to practice it, while real
“pros” practiced their talk once a day for 4 weeks to appear most
relaxed . . .. One is not only dreaming about it, but also having
nightmares.
Meanwhile, I had heard about doctors to go abroad to do
clinically oriented research in the United States. I realized the
enormous potential that such a study might offer. Then, there
was that International Meeting in Brussels, Belgium in Oct 1982
about the “Pathogenic Role of Cationic Proteins: Interaction with
Biological Membranes.” Scientists were reporting about cell sur-
faces and their newly discovered negatively charged surface coat.
Prof. Thoenes wanted me to go, which was an unexpected honor
bestowed upon me not without some envy from other department
members (meaning I had to do some extra autopsy work of dif-
ficult cases). During the ongoing meeting in the lecture hall, he
expected me to simultaneously translate for him. My efforts were
to my utmost, but hopelessly inadequate. In the evening cocktail
meeting, he asked me suddenly with which of the speakers I would
choose to do a postdoctoral training with. I was most impressed
by the clearly structured lecture given by Dr. Helmut Rennke, Pro-
fessor of Pathology at the Brigham and Women’s Hospital (BWH),
Harvard Medical School in Boston, MA, USA. The reception ended
with me having a chance to personally meet the queen, HRH Fabi-
ola of Belgium, under whose patronage the meeting had taken
place. In short, it may pay off having a suit and knowing how to
tie a tie properly, if you are a male.
At the farewell dinner, I happened to sit beside Frank Carone,
M.D., Professor and Head of Pathology at the University of
Chicago. However, far from enjoying myself, I was hard pressed
by the wife of the Weitzman scientist to explain the situation in
Germany before and after the war. Overall, I must have done
well enough to earn an offer to join the Chicago department as
a postdoctoral fellow. Prof. Carone supposedly has three beau-
tiful daughters; maybe my life would have been different if Dr.
Thoenes had not insisted that I apply to Dr. Rennke’s laboratory
at the Harvard Medical School out of prestigious reasons.
In 1983, Dr. Thoenes tried to send me first to Yale University
to Dr. Marilyn Farquhar, the scientist being married to Dr. George
Palade, who was awarded the Nobel Prize for his innovations in
electron microscopy and cell fractionation in 1974. It was the first
time I experienced the “uplifting” feeling of being weighed and
found to be “too light.” So, I got my “wish” writing to Helmut
Rennke in Boston, whom I visited in summer of 1983 to talk about
a potential project to propose to the DFG (the German funding
organization similar but much smaller than the NIH). When I
proposed studying the composition of the immune complexes as
a possible cause for their deposition in the glomerulus, my depart-
ment head did not approve at all – he wanted to know, why protein
would go through the capillary wall. Dr. Rennke and others coin-
cidentally, had already studied this, about that time (but with no
Dr. Google and PubMed at hand, we did not know). Therefore, my
former thesis adviser, Dr. Langer had to travel with me to Boston
as my counselor. While we understood each other quite well, I
felt that this would not necessarily increase my chances of being
accepted.
Unknown to me, in Boston Helmut Rennke had submitted a
NIH grant, of which the idea of immune complex location as
fundamental cause for the clinical symptoms was a key proposal.
In my desperation to answer his question what I wanted to do, I
repeated the idea from Mainz: he convinced me that“building”our
own immune complexes being located subendothelially or subep-
ithelially would be easier than trying to analyze already formed
complexes (which has subsequently been done, too). Coming back
to Mainz with Helmut’s proposal, I was not greeted with enthu-
siasm. On the contrary, I was told that neither scientifically nor
personality-wise or in the subject of Pathology could I possibly be
successful – so, I should rather leave. This was the “birthday gift”
from this department on my 30th. Since Helmut supported me, I
was given a 2-year DFG fellowship abroad. A new part of my life
started at the BWH, a teaching hospital of the Harvard Medical
School, in Boston, MA, USA, on July 1, 1984.
POST-DOCTORAL FELLOW IN BOSTON: RENAL RESEARCH
Going to the US I fulfilled a dream of my mother, who was offered
training as teacher in the US in 1945, but fell ill with rheumatic
fever, convinced that she heard the plane leave overhead, without
her. My father was a medic in the Second World War and at the
age of 18 years was captured in Monte Casino, Italy, in 1944. He
worked as a medic in the POW camp of Fort Devens, a few miles
north of Boston. Thus, I carried an invisible burden to succeed.
My level of expectations and fears could have been hardly
smaller than that of Columbus starting his first voyage in 1492.
My advantage was a much faster and certainly safer travel. I was
greeted warmly, and was able to stay at Helmut’s house until he
and his newly wed wife had helped me to find my own apartment.
In addition, I was equipped with many useful things from other
people’s moves coming from his parents-in-law. This way I learned
the importance of looking for disposed things in the appropriate
room located on each floor of the big apartment buildings: plants,
radio, a cheese fondue set (made in Japan!), and clothing forgotten
in the dryer, among others. However, prices were high: being paid
in German Mark, the exchange rate in 1984 was $1 being about 3
DM: so I had roughly a $1000 to live on. I became good friends
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Fries The wish to cure and the curiosity to investigate
with the subway system. That I did not have a car in America was
probably the most puzzling news for my friends at home. In spite
of having my “own” money, I was expected to work hard, as the
chairman of this department, Ramzi Cotran, M.D., Professor of
Pathology, communicated to me in no uncertain terms.
It took the better of the first half year alone to establish the
appropriate method to position immune complexes by physical
and chemical modification. The first animal experiments took me
about 4 h per animal; later I could do one in about one half hour
(with an assisting hand). I perfused the animals with the differ-
entially charged or sized iron core ferritin molecules in one renal
artery. Its deposition was thereby directed within the layers of the
peripheral capillary loop followed by antibody injection against
ferritin to form an immune complex. Classic pathology techniques
(immune histology, electron microscopy), antibody analysis by
immunodiffusion, leukocyte detection by chloroacetate esterase
staining were among the techniques I learned to employ. This
paper (3) was the exact experimental proof of the observations
that Dr. Karin Sorger had published in Mainz. It never received
quite the attention it may have deserved, since it definitely proved
that subendothelial deposition lead to an inflammatory response,
while subepithelial deposition lead to proteinuria.
At the time, Helmut collaborated with Barry Brenner, M.D.,
Professor of Nephrology, and head of the Department of Nephrol-
ogy, who had become known for his work on hypertensive kidney
damage leading to focal–segmental sclerosis (FSGS). He and his
fellows were convinced that he should get the Nobel Prize for
his discoveries: in anticipation, he had all citations of papers
and abstracts printed on watermark paper, with gilded edges and
leather bound volumes sorted by year. Thus, I subsequently worked
on a second paper, demonstrating by animal experimentation the
importance of podocyte damage in addition to forced filtration by
hypertension following renal ablation (4).
My funniest scientific experience in these years was getting to
the International Conference of Pathology in London, England, in
the summer of 1986 to present two posters. Besides meeting my
parents, whom I had not seen for a while, I succeeded in getting
a stipend paying for the conference. When I suggested the idea of
applying to Helmut at first he was not overjoyed – but with the help
of a snowstorm preventing him leaving the lab I finally managed to
convince him. Furthermore, since the responsible chairperson for
the travel grant section was a French scientist, I decided to write
my application in French, which I had in school as a third language
but I had never used since. Probably, he had a good laugh at the
mistakes I made, but it worked – sometimes learning vocabulary
can be useful after all. In London, I had to visit the US consulate to
extend my J-1 Visa as I was granted an extension by the DFG for
one more year. From then on, I was greeted at US customs with
increased attention: being a German citizen, staying in the US, but
having a J-1 visa from the US consulate in England. I had lots of
explaining to do every single time.
There were different research fellows working with Helmut and
members of his lab, and I marveled at their determination and
skills. However, there is nothing without exceptions. One of the
more colorful characters was a female Ph.D., called Jane. Besides
cross-country skiing in the yard of the medical school with our
male technician on less than an 1′′ of snow (rare in Australia,
where she came from), she was less skilled in doing experimental
work. While harvesting spleens for a fusion experiment to pro-
duce monoclonal antibodies, she stood suddenly in the frame of
the door of our second lab, where I did an experiment with Hel-
mut’s help. “Guess what chaps, my mouse is on fire.” Touching
the mouse with a freshly flamed forceps, she set it ablaze and left
it burning although a sink was readily available right behind her.
Helmut’s lightning quick moves were comparable to that of Speedy
Gonzales. To no one’s surprise, the splenic lymphocytes could not
be used.
The thrill of working with Helmut was based on what today
would be called translational research: a clinical question (Why did
hypertension damage the glomerulus?) was taken into the lab and
analyzed by an experimental approach (different animal models of
hypertension and therapeutical interception of developing dam-
age). The insights from this research were reapplied to the clinical
situation (reducing intraglomerular pressure by ACE inhibitors).
This was and still is today the basic idea behind being a clinician–
scientist: you understand key problems in the disease to be studied,
but are also able to devise an experimental strategy to dissect out
these problems, find a solution, and try to apply that to the clinical
problem, hoping to improve it.
The waste paper baskets can provide unbelievable treasures of
information. I found the invitation to an in situ hybridization
course at the Tufts University Medical School in Boston (1982)
presented with participation of Heinz Höfler, M.D., Professor
Pathology, on sabbatical from Graz, Austria, becoming later Chief
of Pathology at the University Hospital of Munich. In contrast to
the members of my lab at that time, I somehow had the strong
feeling of a new dimension opening for many research fields. But,
how to do this? I learned about the possibility of changing to an
H-Visa, allowing me to stay in the US, provided someone would
actually pay me and give me a position in his or her lab.
There was a rather staggering amount of hurdles I had to over-
come. Talking to Dr. Cotran, he advised me to inquire about a
position in the Department of Tropical Public Health, Harvard
School of Public Health, just across the street from the BWH,
where I had worked so far. The former department head of pathol-
ogy, Gustave Dammin, M.D., Professor of Pathology, who was as
acting chief present at the first kidney transplantation at BWH
in 1954 and being interested in infectious disease, had good con-
nections to this department and recommended that I follow Dr.
Cotran’s suggestions. This department had become famous since
the late Andrew Spielman, Ph.D., Professor of Tropical Public
Health, had identified the tics causing Lyme disease first seen at
Martha’s Vineyard, an island off the coast of Massachusetts.
POST-DOCTORAL FELLOW IN BOSTON: MOLECULAR
MYCOBACTERIOLOGY
So, 1 day I went to Dyann Wirth, Ph.D. and Willi Piessens, MD,
Professors of Public Health, the first being my future direct super-
visor, the latter the future head of the lab I was working in.
My project, changed at the last minute (while they worked on
malaria, Leishmania, and Wucheria bancrofti), was the develop-
ment of DNA probes to identify atypical mycobacteria by PCR
reaction. The project was based on a WHO grant, because HIV-
infected patients were increasingly identified as simultaneously
Frontiers in Medicine | Nephrology March 2015 | Volume 2 | Article 9 | 4
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fries The wish to cure and the curiosity to investigate
having other infections. Since the classical mycobacteria causing
tuberculosis could only be differentiated from atypical mycobac-
teria (being only infectious to immune compromised patients)
when cultured, a new method of identification was needed – that
was my role and my funding. In 1987, PCR was done with different
water baths and a clock being set for each step in at least 50 cycles.
Having a week off, I combined recreation at the Florida Keys
with serious studying of the basics in molecular biology. At the
end, I was at least able to differentiate RNA from DNA: the rest
followed in Boston.
As fate would have it, I was supposed to take over this project
from a female Ph.D., Dr. Rubina Patel, born in Pakistan (Figure 3).
Since mycobacterial studies were her scientific life, she was expect-
edly not pleased by the tactful way this announcement was made,
particularly that she had to show me all her techniques and the
work in a level 3 laboratory. However, while I was in London,
I had the opportunity to visit the British Museum. Here, I had
bought a special wedding gift for Rubina. It was just a hunch: I
bought a book dealing with ancient places in former Persia, which
I had seen on my travels, relating to the Sassanid period and their
monotheistic religion founded by Zarathustra. This was indeed
FIGURE 3 |With Dr. Rubina Patel at the Am Soc of Microbiology
Meeting in New Orleans, 1988.
her religion, since her ancestors were expelled from Persia to Pak-
istan long ago. This is how we started our friendship, which was
being marveled at by many. Without her help, I would have never
ever succeeded in my project. Her meticulous work paired with
her always helpful and friendly nature became a lifelong inspira-
tion. When she finally asked me to use one of my buffers, I felt
that I had been given a most cherished award. I managed to find
specific primers for M. avium (5) and developed a PCR protocol to
use them on mycobacteria samples from patients (6). These were
transported being pre-grown on Lowenstein-Jensen slants in glass
(!) tubes from South America to Geneva, where they were picked
up by one of our researchers going to a conference, and then flown
back to Boston. In case you should wonder about the movies,
showing killer bees in the plane, think again: reality can be much
more frightening. Overall, it was the most interesting time of my
life regarding the different people I met from all over the world
(Figure 4). In my final evaluation the negative comment was . . . .
“worries too much about details of experiments”. A comment with
whom any scientist can live with.
ON TO INSTRUCTOR IN PATHOLOGY IN BOSTON:
MOLECULAR CELL ADHESION AND PDGF
After completing a 2-year and 3 months long, second research
fellowship, I wondered what I would be doing in the future. The
FIGURE 4 | Celebrating with lab colleagues, Department ofTropical
Public Health, Harvard School of Public Health, 1988.
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payment at the School of Public Health was meager. I was not
health insured and had no pension payments. My efforts to return
to Germany were not successful. Again, I talked to Dr. Cotran. He
offered me a position in the lab of Tucker Collins, M.D., Ph.D., Pro-
fessor of Pathology, at the Vascular Research Division at the BWH,
led by Michel Gimbrone, M.D., Professor of Pathology. When I
talked to Tucker, as everyone called him, he was impressed by my
knowledge of animal experimentation but also by the quality of
my sequencing gels. In the fall of 1987, I became part of his lab.
He had spearheaded the generation of a transgenic mouse with
the PDGF – B-chain promoter – β-galactosidase as transgene to
study endothelial cell proliferation. Therefore, he entrusted me
with the first transgenic mouse at the BWH to be analyzed. It
took me the better part of 2 years to characterize and breed three
transgenic mouse lines with different number of transgene copies
in their genome. Luckily, I had seen something of Boston and
the vicinity before this fellowship started, because afterwards free
time, even on the weekends, was very scarce. To my disadvan-
tage, the transgene was not expressed in the endothelium but in
the neurons of brain and spinal cord. At the FASEB meeting in
1990, I presented my data (so far unpublished), which consisted of
many CAT assays and immune histology showing the expression
of the transgene in different brain regions, and in development.
When we wanted to publish our paper back to back with that of
Elaine Raines (PDGF in the brain of Macaque monkeys) in Cell,
I was promised a first authorship. The disappointment was con-
siderable, when we learned that a competing group doing in situ
hybridization had used the knowledge I presented to push through
a paper within 3 months – and got it accepted in Cell. Our paper
was accepted as a joint effort with Drs. Raines and Ross (7). The
lesson learned from this for me was never to talk about “hot”
data at a meeting, which was not accepted for publication before.
The even bigger disappointment was the rejection of this ani-
mal model for a patent by the BWH, while a couple years later it
became one of the favored models for Alzheimer disease by using
the PDGF promoter to target neurons. Further experiments using
this model and others to study epilepsy took up another year of
my time, but never saw the light of day, since PDGF expression
in neuron outgrowth following seizures were falsely thought to
be neglectable by the advisory neuropathologist at the time. I still
see myself sitting in the Boston subway car in summer at almost
100°F with the mouse hippocampi on dry ice, which I had dis-
sected at a collaborating Boston college lab to bring back to my
lab to extract RNA for a Northern blot! At least, our promoter
study, where I characterized the importance of the ETS-class of
transcription factors for the PDGF – B chain expression, was pub-
lished in JBC in 1994 (8). Meanwhile, I had turned to cloning
and characterization of cell adhesion molecules, like the mouse E-
selectin and the rat VCAM-1 (vascular cell adhesion molecule-1)
(9). Working together with Myron Cybulsky, M.D., a post doc at Dr.
Gimbrone’s lab, and today Professor of Laboratory Medicine and
Pathobiology at the Toronto General Hospital/Research Institute
(UHN), we analyzed the functional importance of an alternatively
spliced VCAM – molecule present in endothelial cells (10, 11). I
was granted a Green Card by BWH and an Instructor of Pathology
(the lowest faculty position) in 1992. I was also made a co-author
of an NIH grant by Tucker. In my new position as instructor, I did
a project with Mary Lipscomb, M.D., the head-to-be of Pathology
from the University of Texas Southwestern Medical Center, Dal-
las, TX, USA. Mary and I understood each other quite well, while
we had to adjust to each other’s version of spoken English (hers
being with a Southern accent, mine being more German-British).
My role was to introduce her to techniques like RNA extraction,
frozen section immune histology, and others. Together, we char-
acterized the expression of the rat VCAM-1 and E-selectin (12).
How fruitful collaboration can be, was also shown by our work
with the immunology lab of Laurie Glimcher, Ph.D., at the Har-
vard School of Public Health. With my work of E-selectin, I could
help to demonstrate that transcription factors may act together in
achieving transcriptional initiation (13).
One single event stands out during my stay in Boston: in 1990,
I was part of the long line of people being able to congratulate
Joseph Murray, M.D., Emeritus Professor of Surgery, on his Nobel
Prize in medicine for the first successful kidney transplantation
in 1954 at the BWH. He had to fight for many years before being
accepted, as he said in an interview in 2004, being harassed as
“playing God, disturbing the course of nature or experimenting
on human beings.” In 2014, he died at age 93 years, being an advo-
cate of stem cell research. It is consoling to know that it may pay
off never to give up on something one believes in.
RESIDENCY AT THE BRIGHAM ANDWOMEN’S AND AT
CHILDREN’S HOSPITAL, BOSTON
Eventually, I was asked by Dr. Cotran, whether I wanted to do a
residency at the Brigham in Pathology. Just as it is in Germany,
the US authorities did not accept my medical training and I had
to repeat (and pass) the medical examines (USMLE) and pass a
language test before being accepted. It was consoling to learn that
the Krebs cycle was still in existence, and the anatomy of the heart
had not changed in the15 years since I passed my German boards.
On January 2, 1993, my first day as resident, I started with
the disheartening news that my wife, Anne, had lost our first
child, was another day never to forget. Luckily, we still managed
to have two wonderful children thereafter. Otherwise, residency
was a strenuous but interesting time. I liked the structured way it
was organized, starting with the beginning of the academic year
on July 1, ending on June 30 the following year. We were 20 res-
idents and the schedule was made ahead for the entire year and
working like a clock (but only with 3 weeks of vacation!). The
institution of a chief resident helping the first year residents to
get started successfully was excellent. Additionally, specialties of
cardiac, renal, lung, and later sarcoma pathology could be cho-
sen in the second and third year of a 4-year training. Thus, it was
not “learning by doing” only, as I experienced later in Germany,
but a real one-on-one training with the respective senior pathol-
ogist, of which we had about 40. Signing out cases on a Saturday
morning from 08:00 to 14:00o’clock was a regular event (being
hit by about 200+ glass slides on Friday afternoon to prepare),
as were weekend duties for residents. We did our frozen sections
by ourselves (not the technicians!): nothing is more exhilarating
than a surgeon breathing down your neck, while you try to cut this
miserable piece of tissue. However, if you are successful, this will
bring a very different and more constructive atmosphere of work-
ing together and respecting each other than if the interaction is
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only done by phone. Single rooms were given only to those board
certified pathologists – in other words, training was much harder
than in Germany but also far more efficient, team oriented, and
much more fun! In addition, our end-of-the-year party was always
original and funny (Figure 5).
Ramzi Cotran made every effort that residents were exposed to
different research alternatives since he expected them to become
clinician–scientists and later heads of departments, training other
people in succession, being particularly able to raise interest in
research coming from clinical questions (translational research)
combined with teaching. Already in our first year, we were to
present a case at the so-called Gross-Micro Conference every
2 months: an autopsy case presented from which a scientific prob-
lem was deduced, and presented using your own or data from the
literature to the pathology audience. Many residents did subse-
quent postdoctoral work in one of the many experimental labs.
The department was well funded; figures reached about eight
Million US$ per year.
However, we had also fun in our department and we could even
make fun of Ramzi Cotran. Though it may seem that funding was
ample, fighting to get a NIH grant through was a very difficult task
with temporarily only <10% of all applied grants being funded.
FIGURE 5 | Making fun of our seniors in pathology at the
end-of-the-year party: “Persuasion is a virtue of gods.” Dr. Helmut
Rennke and a resident discussing renal pathology, 1986.
For example, at a Christmas party, one of the junior staff members
acting as Santa Claus was wondering aloud, why Ramzi Cotran –
being otherwise a very diplomatic person – should have advised his
senior researchers to behave rather aggressively toward the NIH.
Our department head had finished a sabbatical in Leiden, at that
time the center of European kidney transplants. Santa Claus pre-
sented pictures of him, however, in the pose of Rambo (putting
his head on that of Sylvester Stallone) and suggesting that the
unexplainable change of attitude came from him being trained as
special force soldier (however, not in Leiden!). Dr. Cotran would
sign several copies of this picture, of which some ended up on
mantelpieces in the respective private homes among traditional
pictures of family members.
I developed a research project with Tucker’s permission (mean-
ing he diverted money so that I could finance my own project). I
published two papers on the in vitro and (for the first time) in vivo
regulation of the NF-κB signaling pathway in the kidneys of mice.
In the attempt to be acceptable for a so-called first award (a first
NIH grant for junior research members) I developed and worked
on these projects together with another postdoc, Levon Kashigian,
Ph.D., today a good friend and currently Professor and Director of
the Centre for Vascular Research at the University of South Wales,
Sydney, NSW, Australia, and Head of the Transcription and Gene
Targeting Group. His encouragement was quite important and
carried me through some tough times. On these two papers, I was
last author – a prerequisite for the grant, and a great gesture from
Tucker (14, 15). However, in Germany, these two papers did not
count toward my habilitation (only first authorship) and cost me
2 more years toward finally fulfilling the required 10 first author
publications in Köln (nowadays only 5 total!), preventing me from
applying for a professorship at a different university successfully.
I decided to do Pediatric Pathology as a specialty. Therefore, I
worked a total of 3 years at Boston Children’s Hospital, where Dr.
Cotran was also the head of this pathology department (Figure 6).
FIGURE 6 | Staff and residents at the Pathology Department, Children’s
Hospital, Boston, 1994: in front (left to right) Dr. van Praagh, Dr. Perez,
Dr. Cotran. I am standing in the last row to the very left.
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In my third and last year, I worked with Richard van Praagh, M.D.,
and his wife Stella, M.D., both Professors of Pediatric Cardiology
and international experts on congenital heart disease. During this
time, I also worked part time as a paid adviser for experimen-
tal research in the laboratory of José Halperin, M.D., Professor of
Hematology, Laboratory of Translational Research at the Harvard
Medical School. We set up the model of Lewis Lung Carcinoma,
worked on evaluating arteriosclerosis by morphometry, and tried
to intercept scar tissue formation and inflammation, where I used
my expertise with the vascular cell adhesion molecule 1.
THE WAY BACK TO GERMANY: KÖLN
With my training as a resident ending, I had to decide whether
I would consider coming back to Germany. With BWH and the
Massachusetts General Hospital expected to merge (“Partners”) –
which from today’s standpoint (2014) never happened to the
degree originally planned – the options were limited, and my first
award (NIH grant for young researchers) needed at least another
round of evaluation, thus another year even if it was eventually
funded. Meanwhile, I had an offer from the new department in
Köln, Hans-Peter Dienes, M.D. This was my last chance for a ticket
home, being 44 years of age in 1997. The 13 years in Boston were
very fruitful but were not appreciated in Germany (quote: “With-
out that time in the US, you would have reached your habilitation
reasonably early”), and again, they did not count as experience
for my pathology position nor for my pension funds! In addition,
I had to repeat pathology training, pass my German pathology
boards in 2000, my specialty boards in molecular pathology in
2001, and finally my habilitation in 2003. As it was custom in
2002 for the habilitation process, I had to prepare 23 Leitz folders
containing copies of all papers and lists of publications and talks,
neatly arranged in easily identifiable sections. The copying alone
cost more than a 1000 DM. Then, I packed all the folders in a big
shopping cart and moved through the entire university hospital
to distribute one each per department (in the subsequent year,
CDs were introduced as means of presenting data). The respective
secretaries greeted me with different degrees of enthusiasm. The
interest was limited regarding the subject of my habilitation thesis
(“Vascular cell adhesion molecule-1: molecular biologic and mol-
ecular pathologic studies regarding its role as vascular and mesan-
gial marker of inflammation”). The review process in my case was
reasonably speedy (5 months) except for the neurosurgery depart-
ment, where – maybe due to a secret admirer – the folder got lost.
Was it all worth it? The question to ask yourself, in my mind,
however, is why do you want to do basic/translational research as
a clinician in the first place? To call yourself a professor: if you
desire the title only for your letter head, then this ordeal – even
if it is shorter than mine – is not for you, and you may be better
served doing clinical studies. Yet, I believe one should try to make
the best out of one’s God given gifts. Moreover, if you should
have the desire to contribute another piece to the eternal puzzle of
mankind, possibly even of some persistent importance, it is defi-
nitely worth a try. However, it helps, when your family is on your
side . . .. (Figure 7).
THE ERA OF MOLECULAR TECHNOLOGY
Thus, being back in Germany – besides trying to overcome all
hurdles including a new beginning for my family – there were
FIGURE 7 | Family and parents (2006) – the only constant support.
again several new techniques in the last 10 years, which changed the
way, we do research today: laser-microdissection, RNA isolation
from fresh and from formalin-fixed, paraffinized tissue, siRNA,
microarray technology, and miRNA. In Harvard, I had learned
that as soon as a new technology appeared on the horizon, one has
to think about how it could be useful for one’s research. As Tucker
told me, one has options: you lead, you follow, or you get out of the
way. Whether you actually have this choice, and which one you will
take in each separate case, may well depend on a variety of factors,
unfortunately, not always under your own control. However, do
not use it just as an excuse – ask yourself what will become of your
plans in the long run.
With my past experience, I was able to get a DFG grant and
established laser-microdissection combined with mRNA analysis
using femtograms of RNA from paraffinized renal biopsies out
of glomerulus-slices (16). All I had was an eager technician fresh
from school, Ms. Tanja Roth, whom I taught in my vacation time
to do ELISA analysis and RT-PCR. In collaboration with the cen-
ter of nephropathology at Ljubljana, Slovenia, we collaborated and
developed a technique to transfer frozen sections at mid-summer
temperatures to Köln in order to extract RNA from glomerular
slices for RT-PCR. The yield of RNA from frozen section versus
paraffinized tissue was almost a thousand-fold higher. All that,
however, was not good enough for the DFG reviewer, a tumor
researcher who worked with milligrams of RNA, having no clue
about the problems I had to face. I was not happy . . .. In addition,
I tried to publish a paper showing laser-microdissected glomeruli
from a lupus patient, showing that in remission previously upreg-
ulated genes were no longer detectable. It was not appealing to the
renal pathology community. A “real” pathologist would be able to
see changes in the microscope. However, changes on gene levels
one cannot appreciate by microscopy until they are developing
into visible damage. It was this pre-damage analysis I was inter-
ested in because it may potentially guide preventive therapy. I felt
I was doing the right thing at too early a time point.
In order not to forget my endothelial roots I managed to col-
laborate with the lab of Claudia Gottstein, Ph.D., Clinic I, Internal
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Medicine at the University of Köln working on tumor endothelium
to induce thrombosis, ultimately using the vascular cell adhesion
molecule-1 as target molecule (17, 18).
THE STEM CELL EUPHORIA
In the first years of the new millenium, the excitement about stem
cell research healing disease was very high, spearheaded by the
attempt to heal myocardial infarction. My efforts to participate
in this development were successful through collaborations with
several clinician–scientists from other departments. By Bernd K.
Fleischmann, M.D., Professor of Physiology, I was engaged to look
at the effects of stem cell infusion in infarcted areas of the mouse
heart (19). The desired healing through rebuilding or mitoses of
the cardiac myocytes was not observed. When omnipotent stem
cells were used, teratomas ensued typically showing differentiation
from all germ layers, while pluripotent stem cells predetermined by
an expression vector for smooth muscle actin did not (20). Similar
results were observed when I collaborated with Jochen Müller-
Ehmsen, M.D., in rat hearts with myocardial infarction tracing
the injected stem cells by RT-PCR for the Y-chromosome (21) or
looking at bone marrow cell deposition in a pig model after bal-
loon occlusion of its coronary arteries (22). Another study with
Manfred Gessler, M.D., Professor of Cardiac Surgery, looking at
lymphangiogenesis in failing hearts suggested that appositional
growth of initial lymphatics, rather than “de novo” genesis from
pluripotent stem cells or sprouting from preexisting venous ves-
sels, may be the predominant mechanism (23, 24). With all the
excitement about the heart, I tried to apply this idea to the kidney,
too. Here, I participated in a project led by Volker Burst, M.D., a
clinician-scientist from our Department of Nephrology (25). We
were looking at the survival and the effect of mesenchymal stem
cells repopulating necrotic tubules following acute renal failure in
the rat, my model from my doctoral thesis. In agreement with the
findings in the heart, the mesenchymal cells were not present long
enough and not in sufficient numbers to be able to play a decisive
role in the repair of tubular damage.
Another important collaboration showed the importance of
mechanical stretch for activation of human mesangial cells from
the glomerulus as it happens in hypertension. With Margarete
Odenthal, Ph.D., and her group from our department, I performed
experiments showing the importance of individual transcription
factors for the promoter activation of smooth muscle actin, a
marker gene of mesenchymal transition (26).
A NEW FOCUS: ENDOTHELIN-1
About 2003, just being finished with my habilitation I was lucky
to meet a clinician (pediatric nephrologist) – researcher from
our Pediatric department, Christoph Licht, M.D. (today Associate
Professor of Pediatrics, Hospital of Sick Children, Toronto, ON,
Canada), working on renal damage in children. He had done a
postdoc working with Masashi Yanigasawa, M.D., Ph.D., a former
investigator at the Howard Hughes Medical Institute and a Pro-
fessor at the University of Texas Medical Center, on the autocrine
role for endothelin-1 in the regulation of proximal tubule NHE3.
I assisted him in evaluating a proteinuric model of renal disease
being treated with endothelin-receptor blockers versus the classi-
cal treatment of ACE inhibitors. Doing this, I remembered that
Tucker had once helped a fellow of Dr. Brenner to clone rab-
bit endothelin-1 in 1992. Therefore – with the delay of almost
14 years – I started a success story investigating endothelin-1with
respect to renal tubular disease.
Looking for a Ph.D. candidate to work with me on this project,
a colleague referred me to Melanie von Brandenstein, in 2006 a
young Master graduate from the Rhein-Bonn Sieg University of
Applied Sciences in St. Augustin, German. First, we demonstrated
the yet unknown existence of the endothelin A-receptor on human
proximal renal tubule cells (27), leading to the activation of the
NF-κB inflammatory signal cascade (28). Then, we established a
novel signaling pathway, showing that in renal tubule cells as well
as in various tumor cell lines, the p65 component of NF-κB, and
the p38α component of the mitogen-activated kinase p38 together
(29) are joined by the α isoform of protein kinase C to establish
a cytoplasmic complex. This complex can transmigrate into the
nucleus, where PKCα interacts with the pri-miRNA15a to prevent
miRNA maturation. After stimulation, the complex is reduced,
less PKCα present in the nucleus, and mature miRNA5a is made
(30). Presenting that research at the International Conference of
Endothelin in Cambridge in 2011, with my support Melanie was
awarded the best presentation and the best poster award. Showing
that miRNA15a was excreted in the urine, we demonstrated that
miRNA15a could be a urinary biomarker for malignant renal cell
carcinoma [von Brandenstein et al. (30)]. This research received
the annual award of the Walter Schultz Stiftung, München, in 2012.
To build an international reputation by trying to answer clini-
cally related questions with basic science methods, which was my
understanding of doing translational research, is difficult when less
and less time can be allotted to do research activities. Hereby, the
responsibility for the lab members is a burden not to be under-
estimated. In 2013, I was finally granted my professorship after
all, which opened new avenues for independent research. At the
same year, we celebrated the 25th birthday of endothelin in Tokyo
(Figure 8).
FIGURE 8 |With Heike Löser, M.D., Julia Straube, BA(!) and Melanie
von Brandenstein, Ph.D. (left to right) at theThirteenth International
Conference on Endothelin (ET-13) inTokyo, 2013, celebrating 25 years
of the discovery of endothelin-1.
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WITH 60 – AHEAD INTO THE FUTURE
In January 2014, turning 60, I received the remark that I will prob-
ably be looking forward to my retirement now. I also experienced
a 30-year-old resident telling me sadly that she still was looking at
35 years of work ahead – what do you think my answer was? Give
me your 35 years!! And why should I stop? On the contrary, there
are so many exciting projects! Recently, we managed to get a patent
on an antibody recognizing a spliced variant of vimentin. Fur-
thermore, I think that we have solved the puzzle of unexplainable
vimentin positivity in benign tumors due to the undiscriminating
use of commercially available antibodies recognizing only the full
length versus the sliced variant, in addition. This insight is very
important in the diagnostic field of uropathology, where misdi-
agnosis of malignant tumors as benign carries potentially grave
consequences for the patient. Thus, with Dr. Stefan Störkel, who
developed the classification of renal tumors, we are looking cur-
rently to enlarge our diagnostic, preoperative potential by finding
new urinary biomarkers for other renal tumors. With Heike Löser,
M.D., a pathology resident having four (!) children, I submit-
ted a paper describing endothelin-mediated downregulation of
a multiple-drug resistant protein due to a miRNA overexpression,
leading to tubular damage (31). Besides all of this, who would
marvel at the daily gall bladders and appendices more than I?
So, if you consider becoming a clinician–scientist and have still
some questions, you may want to talk to me. I would be proud
to be one of your mentors helping you discover the thrill of
being a physician–scientist, and to improve our scientific under-
standing of clinical problems. You need to bring endurance, an
inquisitive mind, and a good portion of imagination. And most
important of all you have to be willing to think outside the box.
There may be hardly a project in which you will not be willing to
give up in between. If you persist you will eventually succeed, be
strengthened, and invigorated for your next project to come.
ACKNOWLEDGMENTS
The author would like to thank Anne M. Schofield-Fries, and his
late parents, Erika and Werner Fries, M.D., for their continued
support. Original research of the author is or has been sup-
ported by the National Institutes of Health, Bethesda; the Deutsche
Forschungsgemeinschaft, Bonn; the WHO/UNDP/World Bank
Program in Tropical Disease; the Köln Fortune Program/Faculty
of Medicine, University of Köln; the Imhoff Stiftung, Köln; the
Nolting Stiftung, Köln; the Walter and Marga Boll Stiftung, Ker-
pen; Jürgen Manchot Stiftung, Düsseldorf, and private donations.
This article was submitted upon invitation by Matthias Barton,
M.D., Editor-in-Chief of Frontiers in Medicine.
REFERENCES
1. Thoenes W, Fries J. Micromorphology of the nephron in experimental tempo-
rary ischemic kidney and in human acute renal failure. In: Schilling A, editor.
Acute Renal Failure: Pathophysiology, its Significance for Intrarenal Surgery and
Prevention. Muenchen: Zuckschwerdt (1998). p. 1–23.
2. Fries JWU, Rumpelt H-J, Thoenes W. Alterations of glomerular podocytic
processes in immunologically mediated glomerular disorders – a morphometric
analysis. Kidney Int (1987) 32:742–8. doi:10.1038/ki.1987.269
3. Fries JWU, Mendrick DL, Rennke HG. Determinants of the expression of
immune complex mediated glomerular injury using ferritin as an exogenous
planted antigen. Kidney Int (1988) 34:333–45. doi:10.1038/ki.1988.186
4. Fries JWU, Sandstrom D, Meyer TW, Rennke HG. Glomerular hypertrophy and
epithelial cell injury modulate progressive glomerulosclerosis in the rat. Lab
Invest (1989) 60:205–18.
5. Fries JWU, Patel RP, Piessens WF, Wirth DF. Genus- and species-specific DNA
probes to identify mycobacteria using the polymerase-chain reaction. Mol Cell
Probes (1990) 4:87–105. doi:10.1016/0890-8508(90)90011-N
6. Fries JWU, Patel RP, Piessens WF, Wirth DF. Detection of untreated mycobacte-
ria by using polymerase chain reaction and specific DNA probes. J Clin Microbiol
(1991) 29:1744–7.
7. Sasahara M, Fries JWU, Raines EW, Gown AM, Westrum LE, Frosch MP, et al.
PDGF B-chain in neurons of the central nervous system, posterior pituitary,
and in a transgenic model. Cell (1991) 64:217–27. doi:10.1016/0092-8674(91)
90223-L
8. Cybulsky MI, Fries JWU, Williams AJ, Sultan P, Davis VM, Gimbrone MA Jr,
et al. Alternative splicing of human VCAM-1 in activated vascular endothelium.
Am J Pathol (1991) 38:815–20.
9. Cybulsky MI, Fries JWU, Williams AJ, Sultan P, Eddy R, Byers M, et al. Gene
structure, chromosomal location and basis for alternative mRNA splicing of
the human VCAM-1 gene. Proc Natl Acad Sci U S A (1991) 88:7859–63.
doi:10.1073/pnas.88.17.7859
10. Williams AJ, Atkins RC, Fries JWU, Gimbrone MA Jr, Cybulski MI, Collins T.
Nucleotide sequence of rat vascular cell adhesion molecule-1 cDNA. Biochim
Biophys Acta (1992) 1131:214–6.
11. Fries JWU,Williams AJ,Atkins RC, Newman W, Lipscomb MF, Collins T. Expres-
sion of VCAM-1 and E-Selectin in an in vivo model of endothelial activation.
Am J Pathol (1993) 143:725–37.
12. Khachigian LM, Fries JWU, Benz MW, Bonthron DT, Collins T. Novel cis-acting
elements in the human platelet-derived growth factor B-chain core promoter
that mediate gene expression in cultured vascular endothelial cells. J Biol Chem
(1994) 269:22647–56.
13. Reimold AM, Grusby MJ, Kosaras B, Fries JWU, Mori R, Maniwa S, et al.
Mice lacking activating transcription factor-2 (ATF-2) display achondroplastic
changes, abnormal Purkinje cell distribution and defective E-selectin induction.
Nature (1996) 379:262–5. doi:10.1038/379262a0
14. Khachigian LM, Collins T, Fries JWU. Nuclear factor-kappa B mediates induc-
tion of vascular cell adhesion molecule-1 in glomerular mesangial cells. Biochem
Biophys Res Commun (1995) 206:462–7. doi:10.1006/bbrc.1995.1065
15. Khachigian LM, Collins T, Fries JWU. N-acetyl cysteine blocks mesan-
gial VCAM-1 and NF-kB expression in vivo. Am J Pathol (1997) 151:
1225–9.
16. Philipp J, Unruh M, Wagener A, Fries JWU, Gottstein C. The in vivo coag-
ulating activity of soluble tissue factor is selectively enhanced on tumor
endothelium by endotoxin. Arterioscler Thromb Vasc Biol (2003) 23:905–10.
doi:10.1161/01.ATV.0000067700.77438.3F
17. Fries JWU, Roth T, Dienes H-P, Weber M, Odenthal M. A novel evalua-
tion method for paraffinized human renal biopsies using quantitative analy-
sis of microdissected glomeruli and VCAM-1 as marker of inflammatory
mesangial activation. Nephrol Dial Transplant (2003) 18:710–6. doi:10.1093/
ndt/gfg443
18. Dienst A, Grunow A, Unruh M, Rabausch B, Nör JE, Fries JWU, et al. Spe-
cific vascular occlusion of murine and human tumor vasculature by VCAM-
1 targeted recombinant fusion proteins. J Natl Cancer Inst (2005) 97:733–4.
doi:10.1093/jnci/dji130
19. Kolossov E, Bostani T, Roell W, Breitbach M, Pillekamp F, Nygren JM, et al.
Engraftment of engineered ES cell-derived cardiomyocytes but not BM cells
restore contractile function to the infarcted myocardium. J Exp Med (2006)
203:2315–27. doi:10.1084/jem.20061469
20. Breitbach M, Bostani T, Roell W, Xia Y, Dewald O, Nygren JM, et al. Potential
risks of bone marrow cell transplantation into infarcted heart. Blood (2007)
110:1362–9. doi:10.1182/blood-2006-12-063412
21. Müller-Ehmsen J, Krausgrill B, Burst V, Schenk K, Neisen UC, Fries JWU, et al.
Effective engraftment but poor mid-term persistance of mononuclear and mes-
enchymal bone marrow cells in rat myocardial infarction. J Mol Cell Cardiol
(2006) 41:876–84. doi:10.1016/j.yjmcc.2006.07.023
22. Dashkevich A, Bloch W, Antonyan A, Fries JWU, Geissler HJ. Morphological
and quantitative changes of the initial myocardial lymphatics in terminal heart
failure. Lymphat Res Biol (2009) 7:21–7. doi:10.1089/lrb.2008.1010
23. Dashkevich A, Bloch W, Antonyan A, Goebel H, Fries JU, Schlensak C, et al.
Immunohistochemical study of remodeling of myocardial lymphatic and blood
Frontiers in Medicine | Nephrology March 2015 | Volume 2 | Article 9 | 10
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fries The wish to cure and the curiosity to investigate
microvascular structures in terminal heart failure: differences between ischemic
and dilated cardiomyopathy. Lymphology (2010) 43:110–7.
24. Tossios P, Krausgill B, Schmidt M, Fischer T, Halbach M, Fries JWU, et al. Role of
balloon occlusion for mononuclear bone marrow cell deposition after intracoro-
nary injection in pigs with reperfused myocardial infarction. Eur Heart J (2008)
29:1911–21. doi:10.1093/eurheartj/ehn218
25. Burst VR, Gillis M, Pütsch F, Herzog R, Fischer JH, Heid P, et al. Poor cell
survival limits the beneficial impact of mesenchymal stem cell transplan-
tation on acute kidney injury. Nephron Exp Nephrol (2010) 114:e107–16.
doi:10.1159/000262318
26. Hirschfeld J, Maurer J, Jung D, Kwiecinski M, Khimji AK, Dienes HP, et al.
Targeting myofibroblasts in model systems of fibrosis by an artifical α-smooth
muscle-actin promoter hybrid. Mol Biotechnol (2009) 43:121–9. doi:10.1007/
s12033-009-9186-4
27. von Brandenstein MG, Abety AN, Depping R, Roth T, Koehler M, Dienes
H-P, et al. A p38-p65 transcription complex induced by endothelin-1 mediates
signal transduction in cancer cells. Biochim Biophys Acta (2008) 1783:1613–22.
doi:10.1016/j.bbamcr.2008.04.003
28. Gerstung M, Roth T, Dienes H-P, Licht C, Fries JWU. Endothelin-1 induces NF-
kB via two independent pathways in human renal tubular epithelial cells. Am
J Nephrol (2007) 27:294–300. doi:10.1159/000101999
29. von Brandenstein M, Depping R, Schäfer E, Dienes H-P, Fries JWU. Protein
kinase Cα regulates nuclear pri-microRNA 15a release as part of endothelin
signaling. Biochim Biophys Acta (2011) 1813:1793–802. doi:10.1016/j.bbamcr.
2011.06.006
30. von Brandenstein M, Pandarakalam JJ, Kroon L, Loeser H, Herden J, Braun
G, et al. MicroRNA15a, inversely correlated to PKCα, is a potential marker to
differentiate between benign versus malignant renal tumors in biopsies and
in urine samples. Am J Pathol (2012) 180:1787–97. doi:10.1016/j.ajpath.2012.
01.014
31. Loeser H, von Brandenstein M, Herschung A, Schlosser M, Buettner R, Fries
JWU. ET-1 Induced downregulation of MRP2 via miRNA 133a – A marker for
tubular nephrotoxicity? Am J Nephrol (2015). (in press).
Conflict of Interest Statement: The author declares that the research was conducted
in the absence of any commercial or financial relationships that could be construed
as a potential conflict of interest.
Received: 18 December 2014; paper pending published: 14 January 2015; accepted: 17
February 2015; published online: 06 March 2015.
Citation: Fries JWU (2015) The wish to cure and the curiosity to investigate –
or how I used my life to become a physician-scientist. Front. Med. 2:9. doi:
10.3389/fmed.2015.00009
This article was submitted to Nephrology, a section of the journal Frontiers in Medicine.
Copyright © 2015 Fries. This is an open-access article distributed under the terms of the
Creative Commons Attribution License (CC BY). The use, distribution or reproduction
in other forums is permitted, provided the original author(s) or licensor are credited
and that the original publication in this journal is cited, in accordance with accepted
academic practice. No use, distribution or reproduction is permitted which does not
comply with these terms.
www.frontiersin.org March 2015 | Volume 2 | Article 9 | 11
